EMPOWER-Lung 1: Baseline Characteristics and Modern Treatment Considerations in NSCLC
Panelists discuss how, at their practices, histology, staging and ECOG performance status guide treatment decisions for advanced non-small cell lung cancer (NSCLC). Compared with EMPOWER-Lung 1, these factors remain crucial. Key biomarkers, such as PD-L1 expression, influence PD-1 inhibitor efficacy. In 2025, treatment options are more personalized with emerging therapies.
Video content above is prompted by the following:
- How does histology, staging and ECOG performance status play into treatment considerations at your practice today, and how do these factors compare to the baseline characteristics of this study?
- What other biomarkers, if any, are important in determining the efficacy of PD-1 inhibitors like cemiplimab before initiating therapy, both in NSCLC and for other indications?
- Overall, how does this patient population compare with those treated in 2025 with immune checkpoint inhibitors or other first-line treatment options for advanced NSCLC?
Study Finds Adherence to Annual Lung Cancer Screening Linked to Higher Detection Rates
March 18th 2025Researchers found that adherence to the first and second annual screenings was 61% and 51%, respectively, with higher lung cancer detection rates observed in those who followed through on these screenings.
Read More
Regeneron Canada Reaches New Agreement Deal for Cancer Drug Libtayo
March 7th 2025The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in different provinces and territories will cover the drug's cost for patients, according to a news release by Regeneron Canada.
Read More
Study Explores Immunotherapy vs. Chemoimmunotherapy Decisions For Advanced Non-Small Lung Cancer
March 5th 2025The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more recent diagnosis and prior glucocorticoid/steroid use.
Read More
